Lin, T., Lee, S. O., Niu, Y., Xu, D., Liang, L., Li, L., . . . Chang, C. (2013). Differential Androgen Deprivation Therapies with Anti-androgens Casodex/Bicalutamide or MDV3100/Enzalutamide versus Anti-androgen Receptor ASC-J9® Lead to Promotion versus Suppression of Prostate Cancer Metastasis. American Society for Biochemistry and Molecular Biology.
Citação norma ChicagoLin, Tzu-Hua, et al. Differential Androgen Deprivation Therapies With Anti-androgens Casodex/Bicalutamide or MDV3100/Enzalutamide Versus Anti-androgen Receptor ASC-J9® Lead to Promotion Versus Suppression of Prostate Cancer Metastasis. American Society for Biochemistry and Molecular Biology, 2013.
Citação norma MLALin, Tzu-Hua, et al. Differential Androgen Deprivation Therapies With Anti-androgens Casodex/Bicalutamide or MDV3100/Enzalutamide Versus Anti-androgen Receptor ASC-J9® Lead to Promotion Versus Suppression of Prostate Cancer Metastasis. American Society for Biochemistry and Molecular Biology, 2013.